BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 17284719)

  • 1. Performance of different microsatellite marker panels for detection of mismatch repair-deficient colorectal tumors.
    Xicola RM; Llor X; Pons E; Castells A; Alenda C; Piñol V; Andreu M; Castellví-Bel S; Payá A; Jover R; Bessa X; Girós A; Duque JM; Nicolás-Pérez D; Garcia AM; Rigau J; Gassull MA;
    J Natl Cancer Inst; 2007 Feb; 99(3):244-52. PubMed ID: 17284719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An optimized pentaplex PCR for detecting DNA mismatch repair-deficient colorectal cancers.
    Goel A; Nagasaka T; Hamelin R; Boland CR
    PLoS One; 2010 Feb; 5(2):e9393. PubMed ID: 20195377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microsatellite instability testing in colorectal carcinoma: choice of markers affects sensitivity of detection of mismatch repair-deficient tumors.
    Hatch SB; Lightfoot HM; Garwacki CP; Moore DT; Calvo BF; Woosley JT; Sciarrotta J; Funkhouser WK; Farber RA
    Clin Cancer Res; 2005 Mar; 11(6):2180-7. PubMed ID: 15788665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated levels of the mismatch repair protein PMS2 are associated with prostate cancer.
    Norris AM; Woodruff RD; D'Agostino RB; Clodfelter JE; Scarpinato KD
    Prostate; 2007 Feb; 67(2):214-25. PubMed ID: 17044039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer.
    Southey MC; Jenkins MA; Mead L; Whitty J; Trivett M; Tesoriero AA; Smith LD; Jennings K; Grubb G; Royce SG; Walsh MD; Barker MA; Young JP; Jass JR; St John DJ; Macrae FA; Giles GG; Hopper JL
    J Clin Oncol; 2005 Sep; 23(27):6524-32. PubMed ID: 16116158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunohistochemistry for PMS2 and MSH6 alone can replace a four antibody panel for mismatch repair deficiency screening in colorectal adenocarcinoma.
    Hall G; Clarkson A; Shi A; Langford E; Leung H; Eckstein RP; Gill AJ
    Pathology; 2010; 42(5):409-13. PubMed ID: 20632815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolated loss of PMS2 expression in colorectal cancers: frequency, patient age, and familial aggregation.
    Gill S; Lindor NM; Burgart LJ; Smalley R; Leontovich O; French AJ; Goldberg RM; Sargent DJ; Jass JR; Hopper JL; Jenkins MA; Young J; Barker MA; Walsh MD; Ruszkiewicz AR; Thibodeau SN
    Clin Cancer Res; 2005 Sep; 11(18):6466-71. PubMed ID: 16166421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations in PMS2, MSH2 and MLH1 expression in human prostate cancer.
    Chen Y; Wang J; Fraig MM; Henderson K; Bissada NK; Watson DK; Schweinfest CW
    Int J Oncol; 2003 May; 22(5):1033-43. PubMed ID: 12684669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microsatellite instability markers for identifying early-onset colorectal cancers caused by germ-line mutations in DNA mismatch repair genes.
    Mead LJ; Jenkins MA; Young J; Royce SG; Smith L; St John DJ; Macrae F; Giles GG; Hopper JL; Southey MC
    Clin Cancer Res; 2007 May; 13(10):2865-9. PubMed ID: 17504984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer.
    Piñol V; Castells A; Andreu M; Castellví-Bel S; Alenda C; Llor X; Xicola RM; Rodríguez-Moranta F; Payá A; Jover R; Bessa X;
    JAMA; 2005 Apr; 293(16):1986-94. PubMed ID: 15855432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical analysis reveals high frequency of PMS2 defects in colorectal cancer.
    Truninger K; Menigatti M; Luz J; Russell A; Haider R; Gebbers JO; Bannwart F; Yurtsever H; Neuweiler J; Riehle HM; Cattaruzza MS; Heinimann K; Schär P; Jiricny J; Marra G
    Gastroenterology; 2005 May; 128(5):1160-71. PubMed ID: 15887099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemistry as first-line screening for detecting colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: a 2-antibody panel may be as predictive as a 4-antibody panel.
    Shia J; Tang LH; Vakiani E; Guillem JG; Stadler ZK; Soslow RA; Katabi N; Weiser MR; Paty PB; Temple LK; Nash GM; Wong WD; Offit K; Klimstra DS
    Am J Surg Pathol; 2009 Nov; 33(11):1639-45. PubMed ID: 19701074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended microsatellite analysis in microsatellite stable, MSH2 and MLH1 mutation-negative HNPCC patients: genetic reclassification and correlation with clinical features.
    Schiemann U; Müller-Koch Y; Gross M; Daum J; Lohse P; Baretton G; Muders M; Mussack T; Kopp R; Holinski-Feder E
    Digestion; 2004; 69(3):166-76. PubMed ID: 15118395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular characterization of the spectrum of genomic deletions in the mismatch repair genes MSH2, MLH1, MSH6, and PMS2 responsible for hereditary nonpolyposis colorectal cancer (HNPCC).
    van der Klift H; Wijnen J; Wagner A; Verkuilen P; Tops C; Otway R; Kohonen-Corish M; Vasen H; Oliani C; Barana D; Moller P; Delozier-Blanchet C; Hutter P; Foulkes W; Lynch H; Burn J; Möslein G; Fodde R
    Genes Chromosomes Cancer; 2005 Oct; 44(2):123-38. PubMed ID: 15942939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microsatellite instability and novel mismatch repair gene mutations in northern Chinese population with hereditary non-polyposis colorectal cancer.
    Sheng JQ; Chan TL; Chan YW; Huang JS; Chen JG; Zhang MZ; Guo XL; Mu H; Chan AS; Li SR; Yuen ST; Leung SY
    Chin J Dig Dis; 2006; 7(4):197-205. PubMed ID: 17054581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics.
    Lagerstedt Robinson K; Liu T; Vandrovcova J; Halvarsson B; Clendenning M; Frebourg T; Papadopoulos N; Kinzler KW; Vogelstein B; Peltomäki P; Kolodner RD; Nilbert M; Lindblom A
    J Natl Cancer Inst; 2007 Feb; 99(4):291-9. PubMed ID: 17312306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer.
    Fallik D; Borrini F; Boige V; Viguier J; Jacob S; Miquel C; Sabourin JC; Ducreux M; Praz F
    Cancer Res; 2003 Sep; 63(18):5738-44. PubMed ID: 14522894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility of screening for Lynch syndrome among patients with colorectal cancer.
    Hampel H; Frankel WL; Martin E; Arnold M; Khanduja K; Kuebler P; Clendenning M; Sotamaa K; Prior T; Westman JA; Panescu J; Fix D; Lockman J; LaJeunesse J; Comeras I; de la Chapelle A
    J Clin Oncol; 2008 Dec; 26(35):5783-8. PubMed ID: 18809606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences and evolution of the methods for the assessment of microsatellite instability.
    Laghi L; Bianchi P; Malesci A
    Oncogene; 2008 Oct; 27(49):6313-21. PubMed ID: 18679418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of performance of 6-mononucleotide site panel and NCI panel for microsatellite instability detection in patients with colorectal adenocarcinoma.
    He L; Yang J; Zhang B; Wang Y; Wang J; Ye Q
    Pathol Res Pract; 2023 Apr; 244():154390. PubMed ID: 36905693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.